AstraZeneca Reports Q3 and Nine-Month 2026 Results
AstraZeneca cited continued strong commercial performance and 12 positive Phase III programme readouts in the year to date.
Related stories
Viatris Commences Tender Offer to Acquire Pacira BioSciences
M impact | EQUITY | Oct 30, 2026, 01:03 PM UTC
LyondellBasell Reports Higher Third-Quarter Revenue, Warns Middle East Recovery Will Be Slow
LyondellBasell reported higher quarterly revenue and said Middle East conditions will likely remain fluid. The body is truncated before details on a potential return to pre-conflic
M impact | EQUITY | Oct 30, 2026, 12:59 PM UTC
JPMorgan Downgrades Coursera to Neutral, Cuts Target to $5
JPMorgan lowered its price target from $8 to $5. The new target implies 7.3% upside from Coursera’s Oct. 29 close of $4.66.
M impact | EQUITY | Oct 30, 2026, 12:56 PM UTC
BofA Downgrades Intel to Neutral, Cuts Price Target to $100
BofA lowered its rating on Intel from Buy to Neutral and reduced its price target from $145 to $100.
M impact | EQUITY | Oct 30, 2026, 12:33 PM UTC
Regeneron Shares Rise More Than 8% Premarket After Q3 Earnings Beat
Regeneron reported stronger-than-expected third-quarter earnings, supported by demand for its eye treatments and higher collaboration revenue from Sanofi. Shares gained more than 8
M impact | EQUITY | Oct 30, 2026, 12:31 PM UTC
European session market picture: S&P 500 -1.1%, Nasdaq 100 -2.59%; EUR/USD +0.1%, WTI +1.86%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 1.1 percent, Nasdaq futures is down 2.59 percent, Dow futures is down 0.1 percent and Russell futures is
M impact | EQUITY | Oct 30, 2026, 12:30 PM UTC